首页> Clinical infectious diseases> Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics

Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics

导出原文传递

翻译打印收藏纠错

第一作者： Papaluca, Timothy

作者： Papaluca, Timothy ^[1] ; Roberts, Stuart K. ^[2] ; Strasser, Simone, I ^[3] ; Stuart, Katherine A. ^[4] ; Farrell, Geoffrey ^[5] ; MacQuillan, Gerry ^[6] ; Dore, Gregory J. ^[7] ; Wade, Amanda J. ^[8] ; George, Jacob ^[9] ; Hazeldine, Simon ^[10] ; O'Beirne, James ^[11] ; Wigg, Alan ^[12] ; Fisher, Leslie ^[13] ; McGarity, Bruce ^[14] ; Sawhney, Rohit ^[15] ; Sinclair, Marie ^[16] ; Thomas, James ^[17] ; Valiozis, Ivan ^[18] ; Weltman, Martin ^[19] ; Wilson, Mark ^[20] ; Woodward, Aidan ^[21] ; Ahlenstiel, Golo ^[22] ; Haque, Mazhar ^[23] ; Levy, Miriam ; Prewett, Emily ; Sievert, William ; Sood, Siddharth ; Tse, Edmund ; Valaydon, Zina ; Bowden, Scott ; Douglas, Mark ; New, Kate ; O'Keefe, Jacinta ; Hellard, Margaret ; Doyle, Joseph ; Stoove, Mark ; Thompson, Alexander J.

作者单位： Alfred Hosp Melbourne ^[1] Royal Hobart Hosp ^[2] Univ Hosp Geelong ^[3] Kirby Inst,UNSW Sydney ^[4] Wollongong Hosp ^[5] Sir Charles Gairdner Hosp ^[6] Royal Adelaide Hosp ^[7] Royal Prince Alfred Hosp ^[8] Blacktown Mt Druitt Hosp ^[9] Univ Melbourne ^[10] Flinders Med Ctr ^[11] Liverpool Hosp ^[12] Fiona Stanley Hosp ^[13] Victorian Infect Dis Reference Lab ^[14] Univ Queensland ^[15] Westmead Hosp ^[16] Canberra Hosp ^[17] St Vincents Hosp Melbourne ^[18] Bathurst Base Hosp ^[19] Nepean Hosp ^[20] Sunshine Coast Univ Hosp ^[21] Monash Univ ^[22] Princess Alexandra Hosp ^[23]

关键词 hepatitis C relapse cirrhosis genotype 3 sofosbuvir/velpatasvir/voxilaprevir SOFOSBUVIR VELPATASVIR VOXILAPREVIR OUTCOMES

发布时间 2022-03-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交